Herve Avet-Loiseau

Summary

Affiliation: CHU de Nantes
Country: France

Publications

  1. ncbi Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation
    Herve Avet-Loiseau
    Laboratory and Clinical Department of Hematology, University Hospital, 9 quai Moncousu, 44093 Nantes, France
    Blood 99:2185-91. 2002
  2. ncbi Role of genetics in prognostication in myeloma
    Herve Avet-Loiseau
    Laboratory of Hematology, and INSERM, U601, University Hospital, 9 quai Moncousu, 44093 Nantes, France
    Best Pract Res Clin Haematol 20:625-35. 2007
  3. doi Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival
    Herve Avet-Loiseau
    Laboratoire d Hematologie, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 1, France
    J Clin Oncol 30:1949-52. 2012
  4. pmc The dChip survival analysis module for microarray data
    Samir B Amin
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard School of Public Health, 450 Brookline Ave, Boston, MA 02215, USA
    BMC Bioinformatics 12:72. 2011
  5. ncbi Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
    Herve Avet-Loiseau
    INSERM Unité 601, Laboratoire d Hematologie, Institut de Biologie, 9 quai Moncousu, 44093 Nantes, France
    Blood 109:3489-95. 2007
  6. doi Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)
    Herve Avet-Loiseau
    Centre Hospitalier Universitaire, Nantes, France
    J Clin Oncol 28:4630-4. 2010
  7. doi Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
    H Avet-Loiseau
    Institut National de la Sante et de la Recherche Medicale INSERM, Unite 892, Nantes, France
    Leukemia 24:623-8. 2010
  8. doi Ultra high-risk myeloma
    Herve Avet-Loiseau
    Laboratoire d Hematologie, Institut de Biologie, Nantes, France
    Hematology Am Soc Hematol Educ Program 2010:489-93. 2010
  9. doi Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials
    Jean Luc Harousseau
    Centre René Gauducheau Bd Jacques Monod 44850 St Herblain, Nantes, France
    J Clin Oncol 27:5720-6. 2009
  10. doi Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
    Philippe Moreau
    University Hospital, Nantes, France
    Blood 118:5752-8; quiz 5982. 2011

Collaborators

Detail Information

Publications35

  1. ncbi Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation
    Herve Avet-Loiseau
    Laboratory and Clinical Department of Hematology, University Hospital, 9 quai Moncousu, 44093 Nantes, France
    Blood 99:2185-91. 2002
    ..The strong correlations we found might be the basis for a novel genetic classification of MM, as has been previously demonstrated for leukemias and lymphomas. Furthermore, our study supports different models for MM oncogenesis...
  2. ncbi Role of genetics in prognostication in myeloma
    Herve Avet-Loiseau
    Laboratory of Hematology, and INSERM, U601, University Hospital, 9 quai Moncousu, 44093 Nantes, France
    Best Pract Res Clin Haematol 20:625-35. 2007
    ..However, even in these genetically defined subgroups, an outcome heterogeneity is observed, suggesting the role of other factors (genetic or otherwise) in disease evolution...
  3. doi Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival
    Herve Avet-Loiseau
    Laboratoire d Hematologie, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 1, France
    J Clin Oncol 30:1949-52. 2012
    ..However, all of these predict shorter survival. To identify patients with a longer life expectancy, we updated the data of patients treated in the IFM (Intergroupe Francophone du Myelome) 99-02 and 99-04 trials...
  4. pmc The dChip survival analysis module for microarray data
    Samir B Amin
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard School of Public Health, 450 Brookline Ave, Boston, MA 02215, USA
    BMC Bioinformatics 12:72. 2011
    ..However, there is no software that can perform survival analysis using SNP array data or draw survival curves interactively for expression-based sample clusters...
  5. ncbi Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
    Herve Avet-Loiseau
    INSERM Unité 601, Laboratoire d Hematologie, Institut de Biologie, 9 quai Moncousu, 44093 Nantes, France
    Blood 109:3489-95. 2007
    ..In myeloma, the genomic aberrations t(4;14) and del(17p), together with beta2-microglobulin level, are important independent predictors of survival. These findings have implications for the design of risk-adapted treatment strategies...
  6. doi Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)
    Herve Avet-Loiseau
    Centre Hospitalier Universitaire, Nantes, France
    J Clin Oncol 28:4630-4. 2010
    ..Patients presenting with either t(4;14) or del(17p) are known to have a short event-free survival (EFS) and overall survival (OS). Some preliminary data suggest that bortezomib is able to overcome these prognostic parameters...
  7. doi Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
    H Avet-Loiseau
    Institut National de la Sante et de la Recherche Medicale INSERM, Unite 892, Nantes, France
    Leukemia 24:623-8. 2010
    ....
  8. doi Ultra high-risk myeloma
    Herve Avet-Loiseau
    Laboratoire d Hematologie, Institut de Biologie, Nantes, France
    Hematology Am Soc Hematol Educ Program 2010:489-93. 2010
    ..However, focusing on fit patients with ISS 3, high proliferation, and poor-risk genetic changes, these patients should probably benefit from dose-dense and prolonged therapeutic schemas, ideally within prospective trials...
  9. doi Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials
    Jean Luc Harousseau
    Centre René Gauducheau Bd Jacques Monod 44850 St Herblain, Nantes, France
    J Clin Oncol 27:5720-6. 2009
    ..The purpose of this study was to analyze the prognostic impact of very good partial response (VGPR) in patients treated with high-dose therapy...
  10. doi Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
    Philippe Moreau
    University Hospital, Nantes, France
    Blood 118:5752-8; quiz 5982. 2011
    ..001). vtD, including reduced doses of bortezomib and thalidomide, yields higher VGPR rates compared with VD and can be considered a new effective triplet combination before HDT/ASCT...
  11. doi Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia
    Patrice Chevallier
    Service d Hematologie Clinique, Centre Hospitalier Universitaire CHU Hotel Dieu, Nantes, France
    J Clin Oncol 26:5192-7. 2008
    ..To determine the antitumor activity and safety of a combination of gemtuzumab ozogamicin (GO), intermediate-dose cytarabine, and mitoxantrone (MIDAM) in patients with refractory or relapsed CD33(+) acute myeloid leukemia (AML)...
  12. ncbi Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy
    Philippe Moreau
    Clinical Hematology Department and the Hematology Laboratory, University Hospital, Nantes, France
    Blood 100:1579-83. 2002
    ..These data emphasized the interest in analyzing these two translocations by fluorescence in situ hybridization in prospective therapeutic trials in order to consider these translocations as distinct entities...
  13. ncbi Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
    Thierry Facon
    Service d Hematologie, Centre Hospitalier Universitaire, Lille, France
    Lancet 370:1209-18. 2007
    ..We assessed whether the addition of thalidomide to this combination, or reduced-intensity stem cell transplantation, would improve survival...
  14. ncbi CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia
    Patrice Chevallier
    Laboratoire d Hematologie, Institut de Biologie, Centre Hospitalier Universitaire, Nantes, France
    Br J Haematol 116:142-50. 2002
    ..In conclusion, CD38 expression and secondary 17p deletion are important poor prognostic indicators, especially in Binet stage A CLL...
  15. ncbi Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level
    Florence Magrangeas
    Laboratory of Hematology, Clinical Hematology Department, University Hospital, Nantes, France
    Blood 103:3869-75. 2004
    ..Furthermore, it showed that this defect did not prevent the activation of the switch process because most of 14q32 translocations observed in LC MM occurred at switch regions...
  16. ncbi Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma
    Philippe Moreau
    Department of Clinical Hematology, University Hospital, Nantes, France
    Haematologica 89:547-51. 2004
    ..The aims of this study were to confirm this hypothesis and to test the prognostic value of CD45 expression in newly diagnosed MM patients...
  17. ncbi 14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia
    Herve Avet-Loiseau
    Laboratory of Hematology, University Hospital, Nantes, France
    Semin Oncol 30:153-5. 2003
    ..Especially in IgM MM, the search for t(11;14) might be useful in difficult cases to discriminate with WM...
  18. doi Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial
    Philippe Moreau
    University Hospital, Nantes, France
    Blood 117:3041-4. 2011
    ..This study is registered with EudraCT (https://eudract.ema.europa.eu; EUDRACT 2005-000537-38) and http://clinicaltrials.gov (NCT00200681)...
  19. pmc Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience
    Herve Avet-Loiseau
    Centre Hospitalier Universitaire, Toulouse, France
    J Clin Oncol 31:2806-9. 2013
    ..However, this has been especially demonstrated in patients age < 66 years treated with intensive approaches. The goal of this study was to address this issue in elderly patients treated with conventional-dose chemotherapy...
  20. ncbi Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants
    Herve Avet-Loiseau
    Laboratory of Hematology, University Hospital, Nantes, France
    Blood 101:1570-1. 2003
    ..Thus, for unknown reasons, t(11;14) is the hallmark of IgM, IgE, and NS MM, (but not IgD MM), with a 5-fold increase of its incidence compared to that of IgG and IgA MM...
  21. ncbi Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease
    Florence Magrangeas
    INSERM U463, Department of Clinical Hematology, University Hospital, Nantes, France
    Blood 101:4998-5006. 2003
    ..This study shows that DNA microarrays enable us to perform a molecular dissection of the bioclinical diversity of MM and provide new molecular tools to investigate the pathogenesis of malignant plasma cells...
  22. pmc Prognostic significance of copy-number alterations in multiple myeloma
    Herve Avet-Loiseau
    L Institut National de la Santé et de la Recherche Médicale U892, Universite de Nantes, Institut de Biologie, 9 quai Moncousu, Nantes, 44093, France
    J Clin Oncol 27:4585-90. 2009
    ..Chromosomal aberrations are a hallmark of multiple myeloma but their global prognostic impact is largely unknown...
  23. doi Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélom
    Olivier Decaux
    L Institut National de la Santé et de la Recherche Médicale, U892, University of Nantes, University, Hospital, Hematology Laboratory, Nantes, France
    J Clin Oncol 26:4798-805. 2008
    ..We used gene expression profiles of myeloma cells obtained at diagnosis to identify broadly applicable prognostic markers...
  24. doi Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies
    Philippe Moreau
    Centre Hospitalier Universitaire Nantes, Nantes, France
    J Clin Oncol 29:1898-906. 2011
    ....
  25. ncbi Stem-cell transplantation in multiple myeloma
    Jean Luc Harousseau
    Department of Hematology, Hotel Dieu, Nantes, France
    Best Pract Res Clin Haematol 18:603-18. 2005
    ..The results of allogeneic SCT remain disappointing due to a high transplant mortality. Strategies combining ASCT and reduced-intensity allogeneic SCT are currently being studied...
  26. ncbi CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis
    Regis Bataille
    INSERM UMR 601, Institute of Biology, Nantes, France
    Leuk Res 32:379-82. 2008
    ..In conclusion, CD117 (c-kit) is aberrantly expressed on a subset of MGUS and MM with a more indolent presentation and is functionally antinomic to CD221 (IGF-1R). CD117 expression could be related to a specific oncogenic pathway in MM...
  27. doi Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
    Herve Avet-Loiseau
    Hematology Laboratory, University Hospital, and Inserm U892, Nantes, France
    Blood 117:2009-11. 2011
    ..28). Moreover, in multivariate analyses, the t(14;16) was not prognostic (P = .39). In conclusion, our data do not support the use of t(14;16)-specific probes in the diagnostic panels of multiple myeloma...
  28. pmc Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma
    Laurence Lodé
    Laboratoire d Hematologie, University Hospital, Nantes, France
    Haematologica 95:1973-6. 2010
    ..In conclusion, we showed that 37% of the myeloma patients with del(17p) present a TP53 mutation versus 0% in patients lacking the del(17p). The prognostic significance of these mutations remains to be evaluated...
  29. pmc Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients
    Florence Magrangeas
    INSERM U892, Universite de Nantes, Nantes, France
    Blood 118:675-8. 2011
    ..3% of samples. Moreover, this catastrophic event confers a poor outcome. Because chromothripsis appears to occur in a single crisis, our results suggest that high-risk MM patients use this novel way of cancer evolution...
  30. ncbi Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study
    Delphine Loussouarn
    Department of Pathology, University Hospital of Nantes, France
    Hum Pathol 37:415-21. 2006
    ..Some meningiomas exhibit HER2 protein overexpression in part induced by gene amplification. However, only HER2 overexpression could represent an independent prognostic factor in meningiomas...
  31. ncbi Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute mye
    Patrice Chevallier
    Service d Hematologie Clinique, Centre Hospitalier Universitaire, 9 quai Moncousu, BP1005, 44093 Nantes Cedex 01, France
    Leuk Res 29:1003-7. 2005
    ..The MIDAM protocol appears to be highly effective especially in patients with poor risk cytogenetic and/or refractory disease...
  32. ncbi Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia
    Nelly Robillard
    Laboratoire d Hematologie, Centre Hospitalier Universitaire, Nantes, France
    Haematologica 90:1516-23. 2005
    ..We aimed at defining whether flow cytometry (FC) techniques can bypass limitations of PCR for MRD determination...
  33. ncbi The impact of genomics on the management of myeloma
    Jill Corre
    Centre Hospitalier Universitaire, Universite, Toulouse, France
    J Natl Compr Canc Netw 9:1200-6. 2011
    ..The use of some of these techniques is now mandatory for the management of patients. Although risk-adapted therapy is not yet a routine practice in myeloma, these molecular changes are essential for the definition of the prognosis...
  34. doi ABT-737 is highly effective against molecular subgroups of multiple myeloma
    Linda Bodet
    INSERM, Unité Mixte de Recherche_S892, Institut de Recherche Thérapeutique de l Université de Nantes, Nantes, France
    Blood 118:3901-10. 2011
    ....
  35. ncbi CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma
    Nelly Robillard
    Laboratory of Hematology and Institut National de la Santé et de la Recherche Médicale INSERM U463, Institute of Biology, Nantes, France
    Blood 102:1070-1. 2003
    ..0001). In conclusion, CD20 expression is associated with small mature plasma cell morphology and with t(11;14) in patients with MM...